Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer

Clinical Therapeutics

Volumn 27, Issue 11, 2005, Pages 1671-1684

  Berry, John ^a  

^a Department of Medicine   (United States)

Author keywords

Adjuvant; Anastrozole; Aromatase inhibitors; Breast cancer; Exemestane; Letrozole

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; GEFITINIB; LETROZOLE; LONAFARNIB; TAMOXIFEN; TESTOLACTONE; TRASTUZUMAB;

ARTHRALGIA; BREAST CARCINOMA; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIUM CARCINOMA; FRACTURE; HOT FLUSH; HUMAN; MEDICAL RESEARCH; MEDLINE; REVIEW; SIDE EFFECT; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

EID: 29144506097     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.11.013     Document Type: Article

References (57)

1. Available at: Breast cancer: Statistics on incidence, survival, and screening Accessed March 9, 2005
2. Nadji M., Gomez-Fernandez C., Ganjei-Azar P., and Morales A.R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers Am J Clin Pathol 123 2005 21 27
3. Guarneri V., and Conte P.F. The curability of breast cancer and the treatment of advanced disease Eur J Nucl Med Mol Imaging 31 Suppl 1 2004 5149 5161
4. Karaer O., Oruc S., and Koyuncu F.M. Aromatase inhibitors: Possible future applications Acta Obstet Gynecol Scand 83 2004 699 706
5. Janicke F. Are all aromatase inhibitors the same? A review of the current evidence Breast 13 Suppl 1 2004 510 518
6. Lonning P., Pfister C., Martoni A., and Zamagni C. Pharmacokinetics of third-generation aromatase inhibitors Semin Oncol 30 Suppl 14 2003 23 32
7. Brodie A. Aromatase inhibitor development and hormone therapy: A perspective Semin Oncol 30 Suppl 14 2003 12 22
8. Hayes D.F. Tamoxifen: Dr. Jekyll and Mr. Hyde? J Natl Cancer Inst 96 2004 895 897
9. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: An overview of the randomised trials Lancet 351 1998 1451 1467
10. Goss P.E. Breast cancer prevention-clinical trials strategies involving aromatase inhibitors J Steroid Biochem Mol Biol 86 2003 487 493
11. Smith I.E. Aromatase inhibitors-extending the benefits of adjuvant therapy beyond tamoxifen Breast 13 Suppl 1 2004 S3 S9
12. Abstract 1 Smith I., Dowsett M., and IMPACT Trialists Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancerin postmenopausal women: The IMPACT trial Breast Cancer Res Treat 82 Suppl 1 2003 S6
13. (Suppl) Cataliotti L., Buzdar A., Noguchi S., and Bines J. Efficacy of PReOperative Arimidex (anastrozole) Compared with Tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer Abstract 46 Eur J Cancer 2 2004 69
14. Eiermann W., Paepke S., Appfelstaedt J. Letrozole Neo-Adjuvant Breast Cancer Study Group Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study Ann Oncol 12 2001 1527 1532
15. Ellis M.J., Coop A., and Singh B. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primarybreast cancer: Evidence from a phase III randomized trial J Clin Oncol 19 2001 3808 3816
16. [published correction appears in Lancet. 2002;360:1520] Baum M., Budzar A.U., Cuzick J. ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial Lancet 359 2002 2131 2139
17. Baum M., Buzdar A., Cuzick J. ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 2003 1802 1810
18. Howell A., Cuzick J., Baum M. ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
19. Abstract S4 Thürlimann B. BIG 1-98: A prospective randomized double blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer Breast 14 Suppl 1 2005 S3
20. Abstract 3 Boccardo F., Rubagotti A., and Amoroso D. Italian Tamoxifen Arimidex (ITA) Trial Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment Breast Cancer Res Treat 82 Suppl 1 2003 S6 S7
21. Abstract 2 Jakesz R., Kaufmann M., and Grant M. ABCSG and GABG Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combinedresults from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial Breast Cancer Res Treat 88 Suppl 1 2004 S7
22. [published correction appears in N Engl J Med. 2004;351:2461] Coombes R.C., Hall E., and Gibson L.J. Intergroup Exemestane Study A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092
23. Abstract 3 Coombes R.C., Hall E., Snowdon C.F., and Bliss J.M. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis Breast Cancer Res Treat 88 Suppl 1 2004 S7
24. Goss P.E., Ingle J.N., and Martino S. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer N Engl J Med 349 2003 1793 1802
25. Goss P.E., Ingle J.N., and Martino S. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTGMA.17 J Natl Cancer Inst 97 2005 1262 1271
26. Bonneterre J., Buzdar A., and Nabholtz J.M. Arimidex Writing Committee Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2001 2247 2258
27. Nabholtz J.M., Buzdar A., Pollak M. Arimidex Study Group Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial J Clin Oncol 18 2000 3758 3767
28. Bonneterre J., Thurlimann B., and Robertson J.F. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or ArimidexRandomized Group Efficacy and Tolerability study J Clin Oncol 18 2000 3748 3757
29. Abstract 515 Paridaens R., Therasse P., and Dirix L. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - arandomized phase III trial of the EORTC Breast Group J Clin Oncol 22 Suppl 1 2004 6S
30. [published correction appears in J Clin Oncol. 2001;19:3302] Mouridsen H., Gershanovich M., and Sun Y. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 2001 2596 2606
31. Mouridsen H., Gershanovich M., and Sun Y. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival andupdate of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2003 2101 2109
32. Buzdar A.U., Jones S.E., Vogel C.L. Arimidex Study Group A phase III trial comparing anastro zole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate inpostmenopausal women with advanced breast carcinoma Cancer 79 1997 730 739
33. Buzdar A.U., Jonat W., Howell A. Arimidex Study Group Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based ona combined analysis of data from two mature phase III trials Cancer 83 1998 1142 1152
34. [published correction appears in Cancer. 1999;85:1010] Kaufmann M., Bajetta E., Dirix L.Y. Exemestane Study Group Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase IIIrandomized double-blind trial J Clin Oncol 18 2000 1399 1411
35. Dombernowsky P., Smith I., and Falkson G. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy andtolerability compared with megestrol acetate J Clin Oncol 16 1988 453 461
36. Geisler J., Haynes B., and Anker G. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated ina randomized, crossover study J Clin Oncol 20 2002 751 757
37. Orlando, Fla. Abstract 217 Bernardi A., Zamagni C., and Di Fabio F. Randomized comparative study on estrogen suppression induced by 3 different aromatase inhibitors in postmenopausal patients with advanced breast cancer Program and abstracts of the 38th Annual Meeting of the American Society of Clinical Oncology May 18-21 2002
38. Abstract 405 Renshaw L., Murray J., and Young O. Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res Treat 88 Suppl 1 2004
39. Abstract 511 Thürlimann B.J., Keshaviah A., and Mouridsen H. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer Proc Am Soc Clin Oncol 23 Suppl 6 2005 10S
40. Boccardo F., Rubagotti A., Amoroso D. Italian Breast Cancer Cooperative Group Sequential ta moxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results ofan Italian Cooperative Study J Clin Oncol 19 2001 4209 4215
41. Winer E.P., Hudis C., and Burstein H.J. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: Status report 2004 J Clin Oncol 23 2005 619 629
42. Rose C., Vtoraya O., and Pluzanska A. An open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole andanastrozole Eur J Cancer 39 2003 2318 2327
43. Thomas R. Examining quality of life issues in relation to endocrine therapy for breast cancer Am J Clin Oncol 26 2003 540 544
44. Thomas R., Godward S., and Makris A. Giving patients a choice improves quality of life: A multi-centre, investigator-blind, randomised, crossover study comparing letrozole withanastrozole Clin Oncol (R Coll Radiol) 16 2004 485 491
45. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition Oncologist 9 Suppl 3 2004 20 26
46. Johnston S.R. Combinations of endocrine and biological agents: Present status of therapeutic and presurgical investigations Clin Cancer Res 11 2005 889s 899s
47. Abstract 1020 Miller W.R., Renshaw L., and Murray J. Microarray analysis of sequential tumour biopsies from patients re ceiving neoadjuvant therapy is able to distinguish sub-populations of breastcancers with differential response to the aromatase inhibitor, letrozole Breast Cancer Res Treat 88 Suppl 1 2004
48. Abstract 1027 Anderson T.J., Dixon M.J., and Murray J. Early changes in tumour Ki67 expression differentiate for pathological (but not clinical) response in breast cancers treated neo-adjuvantly with letrozole Breast Cancer Res Treat 88 Suppl 1 2004
49. Nolvadex [package insert] 2003 AstraZeneca Pharmaceuticals LP Wilmington, Del
50. Fisher B., Costantino J.P., and Wickerham D.L. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
51. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the secondInternational Breast Cancer Intervention Study) Recent Results Cancer Res 163 2003 96 103
52. Available at: National Cancer Institute of Canada The ExCel study January 11, 2005
53. Abstract 5 Fabian C.J., Kimler B.F., and Simonsen M. Reduction in breast epithelial cell proliferation after six months of letrozole in high risk women on hormone replacement therapy with randomperiareolar fine needle aspiration evidence of atypia Breast Cancer Res Treat 88 Suppl 1 2004
54. Abstract S23 Pritchard K. Adjuvant endocrine therapies for pre/perimenopausal women Breast 14 Suppl 1 2005 59
55. Abstract Hausmaninger H. Zoledronic acid prevents bone mineral density loss in premenopausal women receiving adjuvant treatment for hormone receptor-positive breast cancer:Preliminary results of a randomized, multicenter trial of zoledronic acid in patients receiving anastrozole or tamoxifen in combination with goserelin Breast (Scotland) 12 Suppl 1 2003 S43
56. Abstract 1114 Brufsky A., Harker G., Beck T. Z-FAST Study Group Zoledronic acid (ZA) for prevention of cancer-treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): Preliminary results of the Z-FAST trial Breast Cancer Res Treat 88 Suppl 1 2004
57. Abstract 404 Perez E., Josse R.G., and Pritchard K.I. Effect of letrozole versus placebo on bone mineral density in women completing 5 years of adjuvant tamoxifen: NCIC CTG MA.176 Breast Cancer Res Treat 88 Suppl 1 2004